[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cbl-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CBL Gene",5,4,[8,16,23,29,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06504459","Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML",[12],"Phase 2","RECRUITING","2026-08-26T02:17:46.653867Z","2026-05-05T02:43:28.882922Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05849662","A Phase I\u002FII Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:39.267524Z","2026-05-05T02:43:28.528927Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07032727","Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations",[12],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:28.209956Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04888936","Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies",[],"2026-08-26T02:17:59.904383Z","2026-05-13T02:55:06.274852Z",{"nct_id":36,"title":37,"phases":38,"status":39,"updated_at":40,"content_modified":41},"NCT04493138","Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic\u002FMyeloproliferative Neoplasm With FLT3 or CBL Mutations",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:33:22.894436Z","2026-05-05T02:43:28.119922Z"]